Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 04, 2026
TickeronGET DAILY SIGNALS
Why Is bioAffinity Technologies (BIAF) Stock Up +48.12% Today?

Why Is bioAffinity Technologies (BIAF) Stock Up +48.12% Today?

Key Takeaways

  • Shares surged roughly 48.12% intraday on Thursday, extending a multi-day rally for the micro-cap diagnostics company.
  • The primary catalyst was the company's plan to expand its CyPath® Lung test into post-treatment surveillance of lung cancer survivors.
  • Elevated speculative volume and a small float are amplifying the price move, a hallmark of heavily traded micro-cap biotechs.
  • The company's announcement of participation in the H.C. Wainwright Global Investment Conference added to investor attention.
  • Traders are watching for any follow-on clinical validation, financing activity, or profit-taking after the rapid run-up.

Opening Summary

bioAffinity Technologies, Inc. (BIAF), a San Antonio, Texas-based biotechnology company focused on noninvasive diagnostics for early-stage lung cancer detection, saw its stock surge sharply on Thursday. Shares climbed to about $18.93, up from the prior session's close of $12.78, a gain of approximately 48.12%. The advance extended a powerful rally that began earlier in the week after the company announced it was advancing the application of its flagship CyPath® Lung test into the surveillance of lung cancer patients who have completed curative-intent treatment.

Catalyst: CyPath® Lung Expansion Into Cancer Surveillance

The dominant driver behind the stock's surge is BIAF's move to broaden the commercial use of CyPath® Lung, a noninvasive diagnostic that uses flow cytometry and proprietary artificial intelligence to identify malignant cell populations in a patient's sputum. The company said it is advancing the test for ongoing monitoring of lung cancer survivors, positioning it as a complement to CT imaging in detecting recurrence or new cancers.

The addressable market is substantial. According to the American Cancer Society, more than 680,000 Americans were living with a prior lung cancer diagnosis as of January 1, 2025, while the National Cancer Institute estimates another 230,000 new diagnoses in 2026. Published studies report recurrence rates of roughly 20% to 55% for non-small cell lung cancer, underscoring the clinical need for better surveillance tools. CyPath® Lung has demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value in its detection setting, though those figures have not yet been separately validated for post-treatment surveillance.

Secondary Driver: Investor Conference and Corporate Momentum

Adding to the positive sentiment, the company announced that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference in mid-September. The presentation is expected to highlight commercial adoption and momentum for CyPath® Lung, as well as additional diagnostics and therapeutics under development. For a micro-cap name with limited analyst coverage, such events can focus institutional attention and fuel additional buying interest.

Market Context and Trading Activity

The price move is being amplified by extreme trading volume relative to BIAF's small float. Daily volume has reached into the tens of millions of shares at points this week — an enormous figure for a company whose total market capitalization was roughly $7 million to $8 million — indicating intense speculative and momentum-driven activity rather than purely fundamental repositioning. The stock also recently underwent a 1-for-15 reverse stock split effective August 24, 2026, which reduced the share count and can magnify percentage swings in thinly traded names.

The move appears largely company-specific rather than driven by broad market or sector forces. While the biotechnology and diagnostics space has seen periodic enthusiasm for AI-enabled health screening, BIAF's outsized gains this week reflect the CyPath® Lung catalyst and the mechanics of a low-float stock under heavy buying pressure. Traders should note that such parabolic moves can reverse quickly once momentum fades or profit-taking begins.

What Comes Next for BIAF

Looking ahead, investors will be watching for the company's H.C. Wainwright presentation in mid-September, any additional commercial or distribution updates for CyPath® Lung, and progress toward validating the test for post-treatment surveillance. BIAF remains a development-stage company with a history of losses and a continuing need for capital, so financing decisions and cash runway are important considerations. Risks include the lack of separately validated clinical data for the surveillance application, competitive pressure in the lung diagnostics market, and the inherent volatility of a micro-cap stock that has more than tripled in a matter of days.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of automated trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Investors interested in data-driven approaches to volatile names like BIAF can explore the Trending AI Robots section to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BIAF

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BIAF's RSI Indicator descends into oversold zone

The RSI Indicator for BIAF moved into overbought territory on November 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIAF advanced for three days, in 121 of 151 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

BIAF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIAF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BIAF entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.433) is normal, around the industry mean (67.298). P/E Ratio (-2.011) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.229) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. BIAF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIAF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -8%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 23%. ADVB experienced the highest price growth at 8%, while XGN experienced the biggest fall at -47%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -19%. For the same stocks of the Industry, the average monthly volume growth was -30% and the average quarterly volume growth was -53%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 45
SMR Rating: 78
Profit Risk Rating: 87
Seasonality Score: 22 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Industry
N/A
Address
3300 Nacogdoches Road
Phone
+1 210 698-5334
Employees
57
Web
https://www.bioaffinitytech.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.